Pharmaceutical company

Aventis

(AVE)

said a new study shows that its Taxotere drug in combination with other treatments increased the two-year survival rate for patients with lung cancer by 50%.

The study showed that the combination of Taxotere, used primarily in the treatment of metatastic breast cancer and non-small cell lung cancer, with cisplatin produced a 21% two-year survival rate, compared with a 14% survival rate for the standard treatment of cisplatin and vinorelbine for patients suffering from non-small cell lung cancer.

Separately, the study found that Taxotere in combination with carboplatin produced the same effectiveness level as the standard treatment, but the quality of life scores in both Taxotere tests were "significantly better than those in the standard combination arm."

Shares of Aventis were losing about 1% at $70.21.